The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →If your twin has cancer, your risk may be higher than that of an unrelated person, but an identical twin’s diagnosis does not mean you will develop the same cancer. Identical (monozygotic) twins usually share nearly all inherited DNA; fraternal (dizygotic) twins share about half, like ordinary siblings. That genetic closeness changes risk estimates, not certainty.
The right next step depends on the cancer type, the age at diagnosis, whether a pathogenic inherited variant has been identified, and whether the result came from a normal-tissue sample or from the tumor itself. Each twin needs an appropriately ordered clinical assessment and, when indicated, an individual laboratory test.
As an Amazon Associate I earn from qualifying purchases.
The short answer
| Question | What the evidence supports |
|---|---|
| If my identical twin has cancer, will I get it? | Your risk can be higher, but cancer is not inevitable. Inherited variants, environment, behavior, chance, epigenetic differences, mosaicism and acquired tumor mutations all influence the outcome. |
| Do identical twins need the same genetic test? | They need individually ordered and interpreted clinical testing when testing is indicated. Twin identity is not a substitute for laboratory confirmation. |
| Is a tumor DNA test the same as an inherited-cancer test? | No. Tumor testing looks mainly for mutations acquired in cancer cells. Germline testing uses blood, saliva or another normal tissue to look for inherited variants present throughout the body. |
| If my twin has a BRCA or other pathogenic result, do I automatically have it? | You may have the same inherited variant, particularly if you are identical, but you must have a targeted clinical test to establish your own result. A tumor-only finding does not establish that either twin carries an inherited variant. |
What identical and fraternal twins share
Identical, or monozygotic, twins
Monozygotic twins begin when one fertilized egg separates into two embryos. They generally inherit the same DNA sequence, which makes them unusually useful for studying how genes and surroundings contribute to disease. “Generally” matters: development can introduce epigenetic differences, post-zygotic changes and mosaicism, so the twins are not guaranteed to be molecularly identical in every cell.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Fraternal, or dizygotic, twins
Dizygotic twins develop from two eggs fertilized by two sperm. They share, on average, about half of their inherited genetic variants, just as most non-twin siblings do. They can still share a household, prenatal conditions, diet, exposures and social habits, so a difference in cancer concordance between twin types is not a pure measure of genes.
#1 Best Overall
- TOP-SELLING CONSUMER DNA TEST: From your origins in over 3,600+ places around the world to the most connections to living relatives, no other DNA test kit delivers an experience as unique and interactive as AncestryDNA.
- YOUR DATA, YOUR CONTROL: We give you full control over your genetic information. You decide what to share, and with whom.
- DNA + TRAITS: Ever wondered where your freckles came from, or why you hate cilantro? AncestryDNA + Traits lets you discover 75+ genetic traits, allowing you to explore how your genes might have influenced a range of appearance, sensory, performance, nutrient, and other personal characteristics.
- A FEW SIMPLE STEPS: Simply activate your DNA kit online and return your saliva sample in the prepaid package to our state-of-the-art lab. Your results will be available online in roughly six weeks.
- ORIGINS AND INHERITANCE: AncestryDNA is the only DNA test that can show your origins results, DNA matches, and traits by each side of the family, without your parents taking a DNA test.
Both labels describe how the twins originated, not how similar their tumors will be. A cancer mutation that develops in one person’s tumor during adulthood is not automatically present in the co-twin, regardless of twin type.
What large twin studies show about cancer risk
The Nordic Twin Study of Cancer followed 80,309 monozygotic individuals and 123,382 same-sex dizygotic individuals in Denmark, Finland, Norway and Sweden. Participants were followed for a median of 32 years, during which researchers recorded 27,156 incident cancers.
When one twin developed cancer, the estimated cumulative risk of any cancer by age 100 was 46% for monozygotic twins (95% confidence interval, 44%–48%) and 37% for dizygotic twins (95% confidence interval, 36%–38%). The estimate for the overall study population was 32%. The study estimated overall cancer heritability at 33% (95% confidence interval, 30%–37%).
These are population estimates, not a personal forecast. They combine many cancer types, ages and family circumstances. They do not say that an individual identical twin has a 46% personal probability, nor do they predict which cancer might occur, when it might appear, how aggressive it would be or how it would respond to treatment.
Rank #2
- TOP-SELLING CONSUMER DNA TEST: From your origins in over 3,600 places around the world to the most connections to living relatives, no other DNA test kit delivers an experience as unique and interactive as AncestryDNA.
- YOUR DATA, YOUR CONTROL: We give you full control over your genetic information. You decide what to share, and with whom.
- A FEW SIMPLE STEPS: Simply activate your DNA kit online and return your saliva sample in the prepaid package to our state-of-the-art lab. Your results will be available online in roughly six weeks.
- ORIGINS AND INHERITANCE: AncestryDNA provides more precise ancestral origins with greater geographic detail. Our innovative SideView technology takes your results even further by showing your origins and matches by parental side. *Some DNA features require an Ancestry subscription.
- BUILD YOUR FAMILY TREE: Combine what you learn from your DNA results with an Ancestry subscription and gain access to millions of family trees and the world's largest collection of online family history records. *Access to record collections varies depending on subscription level.
Breast-cancer example
An evidence summary from the National Cancer Institute reports a breast-cancer risk estimate of 28.1% when a monozygotic twin had breast cancer, compared with 19.9% when the affected twin was dizygotic. The figures illustrate stronger familial resemblance in identical twins, but they still describe groups rather than an individual’s exact lifetime risk. Personal risk assessment must include the person’s own medical history, the affected twin’s age and tumor features, other relatives, ancestry and any identified pathogenic variant.
Why identical twins can have different cancer outcomes
Shared inherited DNA is only one component of cancer risk. Differences can arise through several mechanisms:
- Environment and behavior: Tobacco exposure, ultraviolet radiation, alcohol, occupational exposures, infections, body weight, reproductive factors, physical activity and screening access can differ between twins.
- Chance: Cells acquire DNA copying errors over time. Random events can affect whether a potentially dangerous clone appears, survives and expands.
- Epigenetic changes: Chemical marks that regulate gene activity can diverge with age and exposure even when the underlying DNA sequence is similar.
- Mosaicism and development: A change arising after the embryo split may occur in some tissues of one twin but not the other.
- Acquired mutations: Most mutations found in a tumor arise during that person’s lifetime and are confined to cancer cells. They are not inherited by the co-twin.
- Tumor evolution: Two people who start with the same susceptibility variant can develop tumors with different additional mutations, histology, stages and treatment responses.
For these reasons, higher concordance among identical twins indicates a stronger inherited contribution; it does not establish genetic destiny.
How to assess your situation after a twin’s diagnosis
Start with the facts that most change the decision: the diagnosed cancer, the twin’s age at diagnosis, the pathology and stage, the complete family history, and the type of genetic test already performed.
Rank #3
- ABOUT THE TEST: The Genetrace DNA Paternity Test helps families conclusively determine if a man is the true father of a child.
- NO HIDDEN FEES: Kit includes all lab fees and sample return costs to test one (1) child and one (1) potential father.
- FAST RESULTS: Get secure, confidential results within 1-2 business days after testing begins. We'll keep you updated every step of the way.
- EASY SAMPLE COLLECTION: No needles, no blood, no doctors. Collect your samples with our easy-to-use mouth swabs, then return them to the lab with the provided prepaid return envelope. It's quick, easy & painless.
- ACCURATE & RELIABLE: Up to 27 genetic markers analyzed for over 99.999% accuracy. All tests performed TWICE in our AABB, ISO 17025 & CLIA accredited laboratory.
1. Record the diagnosis precisely
Ask for the pathology report rather than relying on a description such as “a breast tumor” or “colon cancer.” Note the organ, histologic subtype, age at diagnosis, whether the disease was bilateral or multifocal, and any biomarkers or molecular findings. Those details determine whether hereditary-cancer evaluation is recommended and which test is informative.
2. Build a three-generation family history
Include blood relatives on both sides of the family, their cancer types, ages at diagnosis, multiple primary cancers, known genetic results and whether relatives are alive and available for testing. A counselor can use this history even when no familial variant has yet been found.
3. Find out whether the result is germline or tumor-only
Obtain the laboratory report and identify the specimen. “Blood,” “saliva,” or “normal tissue” generally indicates germline testing; “tumor,” “somatic,” “tumor profiling,” or “next-generation sequencing of cancer tissue” indicates a tumor assay. Some reports explicitly recommend confirmatory germline testing when a possible inherited finding is detected.
Recommended Free Tools
4. Arrange genetic counseling
The National Cancer Institute recommends evaluating personal and family history and generally beginning testing with an affected family member when possible. Pre-test counseling explains what the test can and cannot reveal, possible medical and family implications, and the chance of an uncertain result. Post-test counseling connects the result to screening, risk-reduction options, treatment decisions and testing of relatives.
Rank #4
- MAP YOUR ORIGINS ACROSS 5,000+ REGIONS: Ancestry Composition breaks down your ethnicity across 5,000+ geographic regions worldwide, the most detailed ancestry breakdown of any consumer DNA service. Ancestry Timeline estimates how many generations ago your most recent ancestor from each population lived.
- FIND LIVING RELATIVES: Opt in to DNA Relatives to see up to 1,500 people in the 23andMe database who share DNA with you, from close family to distant cousins, and message them directly. Your Family Tree builds itself automatically based on your DNA.
- DISCOVER WHAT MAKES YOU UNIQUE: See how your DNA may influence physical features, sensory preferences, and habits across 30+ traits, including cilantro taste aversion to hair texture to deep sleep.
- TRACE ANCIENT MIGRATIONS: Maternal and Paternal Haplogroup reports follow your ancestors' migration paths across continents over thousands of years (paternal haplogroup requires a Y chromosome). Find out how much of your ancestry can be traced back to the Neanderthals.
- PRIVATE BY DESIGN: Your DNA data is encrypted, protected, and always under your control. Enhanced security measures are implemented to keep your information safe. Subject to 23andMe’s Terms of Service and Privacy Statement at 23andMe online.
Germline and tumor testing answer different questions
| Feature | Germline testing | Tumor (somatic) testing |
|---|---|---|
| Specimen | Blood, saliva or another normal, non-cancerous tissue | A sample of the cancer, such as a biopsy or surgical specimen |
| Main question | Is there an inherited pathogenic variant present throughout the body? | Which genetic changes arose in this tumor and might guide its treatment? |
| Present in every cell? | An inherited variant is expected in most cells, although mosaicism can complicate interpretation | Usually limited to tumor cells; the finding may be absent from normal tissue |
| Can it be passed to children? | Potentially, depending on the gene and inheritance pattern | Not by itself. A tumor mutation is generally acquired and not inherited |
| Does it test the co-twin? | No. Each twin needs an individually ordered result | No. One twin’s tumor profile cannot be assumed to match the other’s tumor |
| Can it detect inherited risk? | Yes, when the test includes the relevant gene and variant type | Sometimes it flags a possible inherited variant, but it does not replace validated germline confirmation |
The NCI estimates that approximately 5%–10% of all cancers are thought to be caused by harmful inherited genetic changes. Most cancers therefore do not arise from a single inherited variant, even when cancer appears in a family.
If your twin has a pathogenic germline variant
A pathogenic germline result means the laboratory found an inherited change known to increase risk in the relevant clinical context. In identical twins, the co-twin may carry the same variant because their inherited DNA is nearly the same. That possibility is important, but it is not a diagnosis.
- Obtain the exact report. Record the gene, the precise variant description, the laboratory classification and the date. “Positive for a hereditary mutation” is not enough to order a precise follow-up test.
- Ask whether the finding was confirmed as germline. If it came from tumor sequencing, request the recommended confirmatory blood or saliva test through a clinical genetics service.
- Have the co-twin tested individually. The counselor or clinician should order a test that specifically covers the known familial variant, with broader testing considered when the family history warrants it.
- Interpret the result in context. A positive result can affect surveillance, preventive surgery or medication discussions, cancer treatment and testing of children or other relatives. The exact plan depends on the gene, sex, age, prior cancer history and professional guidelines.
- Share the documented result with relatives who may benefit. Cascade testing is most efficient when relatives test for a known familial pathogenic variant rather than starting with an unspecified panel.
A negative targeted result that specifically excludes the known familial pathogenic variant is called a true negative. It can return the person’s inherited risk for that variant toward the general population level, although other personal or family-history factors may still require screening. A negative result when no familial pathogenic variant was established is an uninformative negative; it does not erase the family-history risk.
Free tools Windows power users keep installed
One-click scans. No signup required.
If the twin’s result came from the tumor
Tumor sequencing may identify a mutation that helps select a drug, estimate prognosis or explain how the cancer developed. The same mutation may not exist in the co-twin, even when the twins are monozygotic, because it could have arisen only in the affected person’s tumor.
Best Value
- About HomePaternity: This DNA test will conclusively determine if a man is the biological father of a child using a simple at-home kit including cheek swabs from the father and child.
- Fast Results: Your kit includes Overnight FedEx return to the lab and results will be available within 1-2 days after your sample arrives, in our secure online portal.
- Over 99.999% Confidence: With up to 34 genetic markers examined, we confirm paternity with the highest accuracy, typically 99.999%+. Tests are run twice in our lab, which has obtained over 6 certifications.
- Easy Sample Collection: Collect your samples with mouth swabs, then return in the pre-paid Overnight mailer. Includes testing for 1 child and 1 possible father; can add more participants after kit registration.
- Internal Lab: With over 25 years of experience and over 20 million tests performed, we don’t use third-party labs.
Some tumor findings can also occur in inherited syndromes. When a report raises that possibility, the affected twin should receive confirmatory germline testing. If a germline variant is confirmed, the co-twin and other relatives can pursue targeted testing. If germline testing is negative, the tumor finding may remain a tumor-specific change or may require specialist interpretation because assay limitations and mosaicism can complicate the picture.
If no pathogenic variant is found
Uninformative negative
A broad panel can be negative even when a family has more cancer than expected. Possible explanations include a gene not yet recognized, a variant type the assay did not detect, an inherited factor too small to identify individually, shared environmental exposures or chance. Continue risk assessment based on the family pattern rather than treating the result as a guarantee.
Variant of uncertain significance
A variant of uncertain significance (VUS) is a DNA change whose cancer relevance is not established. It should not be used as proof of increased risk, as a reason for preventive surgery or as the basis for testing relatives as though it were pathogenic. Management should follow the personal and family history and guidance from qualified genetics professionals. Laboratories can later reclassify a VUS, so keep contact information current.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Surveillance and prevention after counseling
Screening is not automatically identical for both twins. A plan may differ according to sex, age, prior operations, pregnancy history, medications, other illnesses, the specific gene and the cancer pattern in the family. A counselor and the appropriate oncology or primary-care team can translate the result into a schedule and decide whether enhanced imaging, specialist examination, medication or risk-reducing surgery is appropriate.
- Keep a written record of diagnoses, pathology, genetic reports and prior screening.
- Report new symptoms promptly rather than waiting for the next routine appointment.
- Ask which findings require urgent evaluation and which are handled at the next scheduled visit.
- Revisit the family history when another relative develops cancer or when a laboratory updates a classification.
- Use clinical hereditary-cancer services rather than direct-to-consumer testing as a substitute for diagnostic evaluation.
Comparison by the questions that change the decision
| Decision factor | Monozygotic twins | Dizygotic twins |
|---|---|---|
| Inherited relatedness | Usually nearly all inherited DNA is shared | About half of inherited variants are shared on average |
| Implication of a confirmed familial germline variant | High reason to arrange targeted testing, but each twin still needs laboratory confirmation | Testing is also appropriate, with the chance of carrying the variant determined by the gene’s inheritance pattern and family relationships |
| Implication of one twin’s tumor mutation | Cannot be assumed to occur in the co-twin | Cannot be assumed to occur in the co-twin |
| Use of cancer-concordance statistics | Shows population-level inherited contribution, not a personal prediction | Provides a sibling-level comparison, also not a personal prediction |
| Testing plan | Clinical genetics review, affected-person testing when possible, then individual co-twin testing if indicated | The same clinical sequence, with family history and the known variant guiding the test |
Common mistakes to avoid
- Equating identical with identical cancer: The same inherited background does not determine tumor type, age, stage or treatment response.
- Using a tumor report as an inherited diagnosis: Confirm a suspected hereditary finding in normal tissue.
- Skipping the co-twin’s test: A laboratory cannot issue a reliable result for one person based solely on another person’s specimen.
- Calling every negative result reassuring: Distinguish a true negative for a known familial variant from an uninformative negative.
- Acting on a VUS: Uncertain means unresolved, not harmful.
- Assuming a panel rules out hereditary risk: Test coverage and scientific knowledge have limits, and family-history-based screening may still be warranted.
- Waiting for certainty before seeking advice: A genetic counselor can often clarify the next step using the existing pathology and family records.
What to bring to a genetics appointment
- The affected twin’s pathology, tumor-testing and treatment reports.
- Any prior germline report, including the laboratory name, gene and variant notation.
- A list of cancers in blood relatives, with ages at diagnosis and sides of the family.
- Your own medical history, screening records, medications and previous biopsies.
- Questions about surveillance, reproductive implications, insurance or disclosure that matter to your family.
The practical rule is simple: treat a twin’s cancer as meaningful family-history information, not as a guaranteed prediction. Identify whether the relevant evidence is inherited or tumor-acquired, test each person through a qualified clinical service, and let the confirmed result and complete family history determine surveillance.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
